

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse gp130 in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human gp130 is observed.
Source	Monoclonal Rat IgG _{2A} Clone # 125623
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse gp130 Gln23-Glu617 (predicted) Accession # Q6PDI9
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	Mouse splenocytes

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

Gp130, the common signal transducing receptor component shared by the functional receptor complexes of the IL-6 family of cytokines, belongs to the class I cytokine receptor family. Binding of IL-6 (IL-11) to either the membrane-anchored or soluble IL-6 R (IL-11 R) initiates the association of IL-6 R (IL-11 R) with gp130 which then undergoes homo-dimerization and signal transduction. With other IL-6 family cytokines, such as LIF and OSM, signal transduction is triggered by the hetero-dimerization of gp130 and LIF R or OSM R.

Gp130 is expressed in all organs examined. Soluble gp130, which apparently arises either from proteolytic cleavage of the membrane-bound receptor or from alternative splicing, has been detected in human serum. The *in vivo* functions of soluble gp130 are not clearly understood. In *in vitro* experiments, natural or recombinant soluble gp130 has been shown to have inhibitory effects on OSM and CNTF activities.

References:

1. Narazaki, M. *et al.* (1993) *Blood* **82**:1120.
2. Taga, T. and T. Kishimoto (1997) *Annu. Rev. Immunol.* **15**:797.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.